Jak2V617F Reversible Activation Shows an Essential Requirement for Jak2V617F in Myeloproliferative Neoplasms
A. Dunbar, R. L. Bowman, Y. Park, F. Izzo, R. M. Myers, A. Karzai, W. Jun Kim, I. Fernandez Maestre, M. R. Waarts, A. Nazir, W. Xiao, M. Brodsky, M. Farina, L. Cai, S. F. Cai, , R. L. Levine
This study shows that reversible activation of Jak2V617F in a mouse model demonstrates its essential role in myeloproliferative neoplasms and highlights the therapeutic potential of mutant-specific JAK2 inhibition.
bioRxiv · May 18, 2022 · PreprintCancer Biology